key: cord-0966782-yzg0s0oh authors: Dimeglio, Chloé; Migueres, Marion; Mansuy, Jean-Michel; Saivin, Sylvie; Miedougé, Marcel; Chapuy-Regaud, Sabine; Izopet, Jacques title: Antibody titers and breakthrough infections with Omicron SARS-CoV-2 date: 2022-02-03 journal: J Infect DOI: 10.1016/j.jinf.2022.01.044 sha: 3e9cf1bce8690771f7f5e629c774062ed8e27178 doc_id: 966782 cord_uid: yzg0s0oh nan Chloé Dimeglio 1,2* dimeglio.c@chu-toulouse.fr, Marion Migueres 1,2 , Jean-Michel Mansuy 1 the Delta SARS-CoV-2 variant. This is consistent with a recent study indicating that a booster Pfizer dose as well as vaccination of previously infected individuals generated an anti-Omicron neutralizing response, with titers 6 -23 times lower against Omicron than those against Delta. [9] . This is also consistent with another study showing that the neutralization titers of anti-Omicron antibodies in the serum of plasma donors were 17 to 22 times lower than they are against the Delta variant [10] . The antibody thresholds found in our study should be compared to those obtained in further studies on other populations. The authors declare no conflict of interest No specific funding Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. The Lancet Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients Antibody titers and protection against a SARS-CoV-2 infection Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Microbiol Spectr Evaluation of the Aptima™ transcriptionmediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing. Viruses Post-vaccination SARS-CoV-2 antibody kinetics and protection duration Considerable escape of SARS-CoV-2 Omicron to antibody neutralization SARS-Cov-2 Omicron: Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern. medRxiv The English text was edited by Dr Owen Parkes.